Bemcentinib

Overview

Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC 50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3 , respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Application

Products | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > TAM Receptor

Product Information

• Catalog No.: HY-15150
• CAS No.: 1037624-75-1
• Molecular Formula: C30H34N8
• Molecular Weight: 506.64
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (2.47 mM); Clear solution
• Availability: In-stock

Source

Original product source